Open AccessPB1756 EFFICACY OF SALVAGE CHEMOTHERAPY REGIMENS IN PATIENTS WITH REFRACTORY OR RELAPSED ACUTE MYELOID LEUKEMIA SINGLE CENTER EXPERIENCE
Author(s) -
Simeonova K.,
Nikolova V.,
Naseva E.,
Stoychov M.,
Yankova T.,
Donchev M.,
Arnaudov G.,
Balazenkou G.,
Guenova M.,
Spasov B.
Publication year - 2019
Publication title -
hemasphere
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.677
H-Index - 11
ISSN - 2572-9241
DOI - 10.1097/01.hs9.0000565532.97640.73
Subject(s) - medicine , flag (linear algebra) , cytarabine , clofarabine , refractory (planetary science) , filgrastim , salvage therapy , chemotherapy , fludarabine , mitoxantrone , myeloid leukemia , surgery , regimen , gastroenterology , granulocyte colony stimulating factor , cyclophosphamide , algebra over a field , physics , mathematics , astrobiology , pure mathematics
Background: Although understanding in the pathology of AML has developed and a variety of new therapies to AML have been found recently, no response to induction therapy still happens in 20–40% and relapse after CR occurs in 50–70% of the patients, respectively, which are called refractory or relapsed AML (R/R AML) Thus, it is necessary to find effective therapies in treating R/R AML patients. Aims: To compare the remission rate and survival between CLARA and FLAG‐Ida salvage chemotherapy in treating patients with refractory or relapsed acute myeloidleukemia (R/R AML). Methods: 18 R/R AML patients with the following demographic and disease characteristics were treated in our center between 2017‐2018(Table 1.). 7 patients with mean age 46.71 years were treated by CLARA salvage chemotherapy as follows:30 mg/m2/day clofarabine (days 1–5); 1 g/m2/day cytarabine(days 1–5) and 300 mcg/day filgrastim (days 0–till neutrophille recovery). While 11 patients with mean age 50 yeras were treated by FLAG‐Ida: 30 mg/m2/day fludarabine(days 1–5), 2 g/m2/day cytarabine (days 1–5), 8 mg/m2/day idarubicine (days 1–5) and 300 mcg/day filgrastim (days 0–till neutrophille recovery). Results: CLARA salvage therapy achieved 57.1 % complete remission rate (CR) and 85.7% overall remission rate (ORR), which was better than FLAG ‐ Ida chemotherapy which realized 36.4% CR and 54.5% ORR. The 30‐day survival rate was higher in CLARA group 85.7% compared to 63.6 in FLAG‐Ida group and it seemed to realize a prolonged OS compared to FLAG – Ida (Table. 3)Summary/Conclusion: In our small group of patients with relapsed/refracoty disease CLARA seemed to be a better tretment option than FLAG ‐ Ida related to both overall response rte and overal survival.